SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cornelissen, J. J. Articles by Anasetti, C. Search for Related Content PubMed PubMed Citation Articles by Cornelissen, J. J. Articles by Anasetti, C. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 March 2001, Vol. 97, No. 6, pp. 1572-1577 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome Jan J. Cornelissen, Michael Carston, Craig Kollman, Roberta King, Adriaan W. Dekker, Bob Löwenberg, and Claudio Anasetti From the University Hospital Rotterdam/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; University Medical Center, Utrecht, The Netherlands; National Marrow Donor Program, Minneapolis, Minnesota; and Fred Hutchinson Cancer Research Center, Seattle, Washington. Between 1988 and 1999, 127 patients with poor-risk acute lymphoblastic leukemia (ALL) received a matched unrelated donor transplant using marrow procured by National Marrow Donor Program (NMDP) collection centers and sent out to 46 transplant centers worldwide. Poor risk was defined by the presence of the translocations t(9;22) (n = 97), or t(4;11) (n = 25), or t(1;19) (n = 5). Sixty-four patients underwent transplantation in first remission (CR1), 16 in CR2 or CR3, and 47 patients had relapsed ALL or primary induction failure (PIF). Overall survival at 2 years from transplant was 40% for patients in CR1, 17% in CR2/3, and 5% in PIF or relapse. Treatment-related mortality (TRM) and relapse mortality, estimated as competing risk factors, were 54% and 6%, respectively, in CR1, 75% and 8% in CR2/3, and 64% and 31% in PIF or relapse. Currently 23 CR1 patients are alive and free of disease with a median follow-up of 24 months (range, 3-97). Multivariable analysis showed that CR1, shorter interval from diagnosis to transplantation, DRB1 match, negative cytomegalovirus (CMV) serology (patient and donor), and presence of the Philadelphia chromosome, t(9;22), were independently associated with better disease-free survival (DFS). Transplantation in CR and presence of t(9;22) were associated with lower risk of relapse. Shorter interval from diagnosis to transplantation, DRB1-match, negative CMV, higher marrow cell dose, and Karnofsky score of 90 or higher were associated with less TRM. These results indicate that, despite a relatively high TRM, the low relapse rate resulted in a 37% ± 13% DFS for CR1 patients, comparing favorably to results obtained with chemotherapy alone and matching results following HLA-identical sibling transplantation. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: I. Iacobucci, C. T. Storlazzi, D. Cilloni, A. Lonetti, E. Ottaviani, S. Soverini, A. Astolfi, S. Chiaretti, A. Vitale, F. Messa, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP) Blood, September 3, 2009; 114(10): 2159 - 2167. [Abstract] [Full Text] [PDF] M. B. Tomblyn, M. Arora, K. S. Baker, B. R. Blazar, C. G. Brunstein, L. J. Burns, T. E. DeFor, K. E. Dusenbery, D. S. Kaufman, J. H. Kersey, et al. Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome J. Clin. Oncol., August 1, 2009; 27(22): 3634 - 3641. [Abstract] [Full Text] [PDF] J. J. Cornelissen, B. van der Holt, G. E. G. Verhoef, M. B. van 't Veer, M. H. J. van Oers, H. C. Schouten, G. Ossenkoppele, P. Sonneveld, J. Maertens, M. van Marwijk Kooy, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison Blood, February 5, 2009; 113(6): 1375 - 1382. [Abstract] [Full Text] [PDF] D. Hoelzer and N. Gokbuget Allogeneic Stem Cell Transplant in Acute Lymphoblastic Leukemia: Who and When? ASCO Educational Book, January 1, 2009; 2009(1): 355 - 359. [Abstract] [Full Text] [PDF] D. I. Marks, W. S. Perez, W. He, M.-J. Zhang, M. R. Bishop, B. J. Bolwell, C. N. Bredeson, E. A. Copelan, R. P. Gale, V. Gupta, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission Blood, July 15, 2008; 112(2): 426 - 434. [Abstract] [Full Text] [PDF] A. H. Goldstone, S. M. Richards, H. M. Lazarus, M. S. Tallman, G. Buck, A. K. Fielding, A. K. Burnett, R. Chopra, P. H. Wiernik, L. Foroni, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Blood, February 15, 2008; 111(4): 1827 - 1833. [Abstract] [Full Text] [PDF] H. M. Lazarus and S. Luger Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion Hematology, January 1, 2007; 2007(1): 444 - 452. [Abstract] [Full Text] [PDF] I. Yakoub-Agha, F. Mesnil, M. Kuentz, J. M. Boiron, N. Ifrah, N. Milpied, S. Chehata, H. Esperou, J.-P. Vernant, M. Michallet, et al. Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen-Identical Siblings Versus Human Leukocyte Antigen-Allelic-Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy J. Clin. Oncol., December 20, 2006; 24(36): 5695 - 5702. [Abstract] [Full Text] [PDF] B. Wassmann, H. Pfeifer, N. Goekbuget, D. W. Beelen, J. Beck, M. Stelljes, M. Bornhauser, A. Reichle, J. Perz, R. Haas, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) Blood, September 1, 2006; 108(5): 1469 - 1477. [Abstract] [Full Text] [PDF] M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, T. Kobayashi, Y. Ueda, M. Takeuchi, S. Miyawaki, et al. High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group J. Clin. Oncol., January 20, 2006; 24(3): 460 - 466. [Abstract] [Full Text] [PDF] B. Wassmann, H. Pfeifer, M. Stadler, M. Bornhauser, G. Bug, U. J. Scheuring, P. Bruck, M. Stelljes, R. Schwerdtfeger, N. Basara, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood, July 15, 2005; 106(2): 458 - 463. [Abstract] [Full Text] [PDF] S. Lee, Y.-J. Kim, C.-K. Min, H.-J. Kim, K.-S. Eom, D.-W. Kim, J.-W. Lee, W.-S. Min, and C.-C. Kim The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Blood, May 1, 2005; 105(9): 3449 - 3457. [Abstract] [Full Text] [PDF] M. Girgis, C. Hallemeier, W. Blum, R. Brown, H.-s. Lin, H. Khoury, L. T. Goodnough, R. Vij, S. Devine, M. Wehde, et al. Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide Blood, April 15, 2005; 105(8): 3035 - 3041. [Abstract] [Full Text] [PDF] O. G. Ottmann and B. Wassmann Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Hematology, January 1, 2005; 2005(1): 118 - 122. [Abstract] [Full Text] [PDF] M. Towatari, M. Yanada, N. Usui, J. Takeuchi, I. Sugiura, M. Takeuchi, F. Yagasaki, Y. Kawai, S. Miyawaki, S. Ohtake, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia Blood, December 1, 2004; 104(12): 3507 - 3512. [Abstract] [Full Text] [PDF] T. R. Chauncey Transplantation for adult ALL-typing and timing Blood, November 15, 2004; 104(10): 2998 - 2999. [Full Text] [PDF] M. Hunault, J.-L. Harousseau, M. Delain, M. Truchan-Graczyk, J.-Y. Cahn, F. Witz, T. Lamy, B. Pignon, J.-P. Jouet, R. Garidi, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial Blood, November 15, 2004; 104(10): 3028 - 3037. [Abstract] [Full Text] [PDF] E. W. Petersdorf, C. Anasetti, P. J. Martin, T. Gooley, J. Radich, M. Malkki, A. Woolfrey, A. Smith, E. Mickelson, and J. A. Hansen Limits of HLA mismatching in unrelated hematopoietic cell transplantation Blood, November 1, 2004; 104(9): 2976 - 2980. [Abstract] [Full Text] [PDF] M. Harata, Y. Soda, K. Tani, J. Ooi, T. Takizawa, M. Chen, Y. Bai, K. Izawa, S. Kobayashi, A. Tomonari, et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells Blood, September 1, 2004; 104(5): 1442 - 1449. [Abstract] [Full Text] [PDF] M. G. Kiehl, L. Kraut, R. Schwerdtfeger, B. Hertenstein, M. Remberger, N. Kroeger, M. Stelljes, M. Bornhaeuser, H. Martin, C. Scheid, et al. Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission J. Clin. Oncol., July 15, 2004; 22(14): 2816 - 2825. [Abstract] [Full Text] [PDF] D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. J. Giles, S. M. Kornblau, G. Garcia-Manero, M. J. Keating, M. Andreeff, S. Jeha, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood, June 15, 2004; 103(12): 4396 - 4407. [Abstract] [Full Text] [PDF] M. Boeckh and W. G. Nichols The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy Blood, March 15, 2004; 103(6): 2003 - 2008. [Abstract] [Full Text] [PDF] B. Wassmann, H. Pfeifer, U. J. Scheuring, A. Binckebanck, N. Gokbuget, J. Atta, P. Bruck, H. Rieder, C. Schoch, L. Leimer, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib Blood, February 15, 2004; 103(4): 1495 - 1498. [Abstract] [Full Text] [PDF] S. Lee, D.-W. Kim, Y.-J. Kim, N.-G. Chung, Y.-L. Kim, J.-Y. Hwang, and C.-C. Kim Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia Blood, October 15, 2003; 102(8): 3068 - 3070. [Abstract] [Full Text] [PDF] M. B. Maris, D. Niederwieser, B. M. Sandmaier, B. Storer, M. Stuart, D. Maloney, E. Petersdorf, P. McSweeney, M. Pulsipher, A. Woolfrey, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Blood, September 15, 2003; 102(6): 2021 - 2030. [Abstract] [Full Text] [PDF] D. Niederwieser, M. Maris, J. A. Shizuru, E. Petersdorf, U. Hegenbart, B. M. Sandmaier, D. G. Maloney, B. Storer, T. Lange, T. Chauncey, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Blood, February 15, 2003; 101(4): 1620 - 1629. [Abstract] [Full Text] [PDF] A. Dominietto, T. Lamparelli, A. M. Raiola, M. T. Van Lint, F. Gualandi, G. Berisso, S. Bregante, C. di Grazia, M. Soracco, A. Pitto, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation Blood, December 1, 2002; 100(12): 3930 - 3934. [Abstract] [Full Text] [PDF] O. G. Ottmann, B. J. Druker, C. L. Sawyers, J. M. Goldman, J. Reiffers, R. T. Silver, S. Tura, T. Fischer, M. W. Deininger, C. A. Schiffer, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias Blood, August 28, 2002; 100(6): 1965 - 1971. [Abstract] [Full Text] [PDF] A. E. Woolfrey, C. Anasetti, B. Storer, K. Doney, L. A. Milner, E. L. Sievers, P. Carpenter, P. Martin, E. Petersdorf, F. R. Appelbaum, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children Blood, March 15, 2002; 99(6): 2002 - 2008. [Abstract] [Full Text] [PDF] S. A. Klein, S. Hermann, C. F. Dietrich, D. Hoelzer, H. Martin ;, and D. Bunjes Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188-labeled anti-CD66 monoclonal antibodies Blood, March 15, 2002; 99(6): 2270 - 2271. [Full Text] [PDF] R. Chakraverty, K. Peggs, R. Chopra, D. W. Milligan, P. D. Kottaridis, S. Verfuerth, J. Geary, D. Thuraisundaram, K. Branson, S. Chakrabarti, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood, February 1, 2002; 99(3): 1071 - 1078. [Abstract] [Full Text] [PDF] D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski Acute Lymphoblastic Leukemia Hematology, January 1, 2002; 2002(1): 162 - 192. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020